MDMA Rejection Raises New Questions On Psychedelic Drug Clinical Trials

(MENAFN- Investor Brand Network) The U.S. Food and Drug Administration (FDA) recently
rejected an application
to approve the use of MDMA as a treatment for post-traumatic stress disorder (PTSD). The MDMA formulation, developed by Lykos Therapeutics, would have been administered in combination with psychotherapy if it had been approved.

In its rejection, the federal agency requested for more clinical trials to be done to gather additional data on the drug's effectiveness and...

Read More>>

About PsychedelicNewsWire

PsychedelicNewsWire
(“PNW”) is a specialized communications platform with a focus on all aspects of psychedelics and the latest developments and advances in the psychedelics sector. It is one of 60+ brands within
the
Dynamic Brand Portfolio
@
IBN
that delivers :
(1) access to a vast network of wire solutions via
InvestorWire
to efficiently and effectively reach a myriad of target markets, demographics and diverse industries ;
(2) article and
editorial syndication to 5,000+ outlets ;
(3) enhanced
press release enhancement
to ensure maximum impact ;
(4)
social media distribution
via IBN to millions of social media followers ;
and (5) a full array of tailored
corporate communications solutions . With broad reach and a seasoned team of contributing journalists and writers, PNW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today's market, PNW brings its clients unparalleled recognition and brand awareness. PNW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from PsychedelicNewsWire, text“Groovy” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit

Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published:
/Disclaimer

PsychedelicNewsWire
San Francisco, CA

415.949.5050 Office
[email protected]

PsychedelicNewsWire is powered by
IBN

MENAFN10012025000224011066ID1109075703